Researchers from Auburn University, partnering with the University of Basel in Switzerland, have discovered a new way to make ...

Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, ...

Scientists at Auburn University have made an important discovery that could improve cancer treatments. Just like a coach ...

Media ReleaseMature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Checkpoint Therapeutics' cosibelimab shows strong efficacy in treating cSCC. Learn why CKPT stock could see significant gains ...

The PERLA trial showed consistent OS benefits across various PD-L1 tumor proportion scores, favoring Jemperli over Keytruda.

Key data: These results compare favourably to the 22.0-month median OS, 9.0-month median PFS, and 24-month OS rate of 45.5% from a registrational trial of anti-PD-1 and doublet chemotherapy in ...

The main difference is BNT327 targets PD-L1 while ivonescimab engages PD-1. On an earnings call last week, BioNTech CEO Ugur ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study ...

BioNTech is investing in a promising space in oncology by acquiring Biotheus’ PD-L1 and VEGF bispecific antibody.